Millipore Sigma Vibrant Logo

401003 (±)-Ibuprofen - CAS 15687-27-1 - Calbiochem

401003
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

Empirical FormulaCAS #
C₁₃H₁₈O₂ 15687-27-1

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
401003-1GM
Retrieving availability...
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 1 gm
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewA nonsteroidal anti-inflammatory drug (NSAID) that acts as a reversible and competitive inhibitor of cyclooxygenase 1 (COX-1) (IC50 = 4.85 µM). Inhibits COX-2 at higher concentrations (IC50 = 223 µM). Blocks aspirin inactivation of COX-1 (EC50 antagonism of 200 µM aspirin = 290 nM). Shown to reduce the total Aβ secretion (Amyloid β40 and 42) in human neuronal cells and offers neuroprotection against glutamate-, nitric oxide-, and superoxide-induced damage. Reported to activate peroxisome proliferator-activated receptors (PPAR) α and γ in both CV-1 and C3H10T1/2 cells (~100 µM-500 µM).
      Catalogue Number401003
      Brand Family Calbiochem®
      Synonyms[(±)-2-(4-Isobutylphenyl)-propionic Acid
      References
      ReferencesAsanuma, M., et al. 2001. J. Neurochem. 76, 1895.
      Blasko, I., et al. 2001. Neurobiol. Dis. 8, 1094.
      Ouellet, M., et al. 2001. Proc. Natl. Acad. Sci. USA 98, 14583.
      Casper, D., et al. 2000. Neurosci. Lett. 289, 201.
      Lambat, Z., et al. 2000. Metab. Brain Dis. 15, 249.
      Lim, G.P., et al. 2000. J. Neurosci. 20, 5709.
      Ogawa, O., et al. 2000. Eur. J. Pharmacol. 408, 137.
      Wyss-Coray, T., and Mucke, L. 2000. Nat. Med. 6, 973.
      Lehmann, J.M., et al. 1997. J. Biol. Chem. 272, 3406.
      Boneburg, E.M., et al. 1996. J. Clin. Pharmacol. 36, 16S.
      Mitchell, J.A., et al. 1994. Proc. Natl. Acad. Sci. USA 90, 11693.
      Product Information
      CAS number15687-27-1
      ATP CompetitiveY
      FormWhite solid
      Hill FormulaC₁₃H₁₈O₂
      Chemical formulaC₁₃H₁₈O₂
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetCOX-1
      Primary Target IC<sub>50</sub>4.85 µM against COX-1
      Purity≥98% by titration
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSMU6640000
      Safety Information
      R PhraseR: 22

      Harmful if swallowed.
      S PhraseS: 36

      Wear suitable protective clothing.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Harmful
      Storage +15°C to +30°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      (±)-Ibuprofen - CAS 15687-27-1 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      (±)-Ibuprofen - CAS 15687-27-1 - Calbiochem Certificates of Analysis

      TitleLot Number
      401003

      References

      Reference overview
      Asanuma, M., et al. 2001. J. Neurochem. 76, 1895.
      Blasko, I., et al. 2001. Neurobiol. Dis. 8, 1094.
      Ouellet, M., et al. 2001. Proc. Natl. Acad. Sci. USA 98, 14583.
      Casper, D., et al. 2000. Neurosci. Lett. 289, 201.
      Lambat, Z., et al. 2000. Metab. Brain Dis. 15, 249.
      Lim, G.P., et al. 2000. J. Neurosci. 20, 5709.
      Ogawa, O., et al. 2000. Eur. J. Pharmacol. 408, 137.
      Wyss-Coray, T., and Mucke, L. 2000. Nat. Med. 6, 973.
      Lehmann, J.M., et al. 1997. J. Biol. Chem. 272, 3406.
      Boneburg, E.M., et al. 1996. J. Clin. Pharmacol. 36, 16S.
      Mitchell, J.A., et al. 1994. Proc. Natl. Acad. Sci. USA 90, 11693.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision28-April-2008 JSW
      Synonyms[(±)-2-(4-Isobutylphenyl)-propionic Acid
      DescriptionA nonsteroidal anti-inflammatory drug (NSAID) that acts as a reversible, competitive, non-selective cyclooxygenase (COX) inhibitor (IC50 = 4.85 µM for purified COX-1 and 223 µM for purified COX-2). Also reported to inhibit COX-1 and COX-2 activity in intact bovine aortic endothelial cells (BAEC) (IC50 = 7 µM for COX-1 and 72.7 µM for COX-2). Potently blocks aspirin inactivation of COX-1 (EC50 antagonism of 200 µM aspirin ~290 nM for ovine COX-1). Decreases the secretion of total Aβ (Amyloid β40&42) by human neuronal cells and offers neuroprotection against glutamate-, nitric oxide- and superoxide-induced damage. Activates peroxisome proliferator activated receptors α and γ in both CV-1 and C3H10T1/2 cells (~100 µM - 500 µM).
      FormWhite solid
      CAS number15687-27-1
      RTECSMU6640000
      Chemical formulaC₁₃H₁₈O₂
      Structure formulaStructure formula
      Purity≥98% by titration
      SolubilityDMSO (5 mg/ml) or Ethanol (1 mg/ml)
      Storage +15°C to +30°C
      Protect from light
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Harmful
      Merck USA index14, 4881
      ReferencesAsanuma, M., et al. 2001. J. Neurochem. 76, 1895.
      Blasko, I., et al. 2001. Neurobiol. Dis. 8, 1094.
      Ouellet, M., et al. 2001. Proc. Natl. Acad. Sci. USA 98, 14583.
      Casper, D., et al. 2000. Neurosci. Lett. 289, 201.
      Lambat, Z., et al. 2000. Metab. Brain Dis. 15, 249.
      Lim, G.P., et al. 2000. J. Neurosci. 20, 5709.
      Ogawa, O., et al. 2000. Eur. J. Pharmacol. 408, 137.
      Wyss-Coray, T., and Mucke, L. 2000. Nat. Med. 6, 973.
      Lehmann, J.M., et al. 1997. J. Biol. Chem. 272, 3406.
      Boneburg, E.M., et al. 1996. J. Clin. Pharmacol. 36, 16S.
      Mitchell, J.A., et al. 1994. Proc. Natl. Acad. Sci. USA 90, 11693.